AbbVie Inc

US

ABBV

Health Care

167.89 ₽

Current price

Sell
167.89 ₽

Target price 00%

Ranks rating

76

  • Position in sub-industry

    771 / 1361

  • Position in country

    11036 / 14179

  • Return on Assets, %

    3.5

    -40.3

  • Net income margin, %

    5.7

    -180

  • EBITDA margin, %

    39.9

    -168.2

  • Debt to Equity, %

    573.2

    3.2

  • Intangible assets and goodwill, %

    65.2

    0.2

  • Revenue CAGR 3Y, %

    5.8

    12.5

  • Total Equity change 1Y, %

    -40

    -9

  • Revenue Y, % chg

    -6.5

    0

  • P/E

    59.6

    31

  • P/BV

    27.6

    1.8

  • P/S

    5.2

    10.3

  • EV/S

    6.1

    7.5

  • EV/EBITDA

    13.1

    -1.6

  • Average Analyst recommendation

    Hold

    Hold

  • Average upside forecasts, %

    16.7

    131.1

  • Forward P/E

    14.1

    21.4

  • Dividend Yield, %

    3.7

    1.1

  • Forward Dividend Yield, %

    3.8

    0.1

  • Expected dividend per share

    6.2

    0

  • Payout Ratio, %

    220.8

    0

  • Dividend Ex Date

    2024-04-12

Get an analytical review of this company

Competitors

Ranks

  • Vertex Pharmaceuticals Inc

    00%

  • Regeneron Pharmaceuticals Inc

    00%

  • Gilead Sciences Inc

    00%

  • Biomarin Pharmaceutical Inc

    00%

  • Seagen Inc

    00%

  • Amgen Inc

    00%

  • Moderna Inc

    00%

  • Alnylam Pharmaceuticals Inc

    00%

  • AbbVie Inc

    00%

  • Biogen Inc

    00%

Ready-made portfolio of the best Russian stocks

  • Created by artificial intelligence
  • Verified by analysts
  • Available even to beginners

Company information

  • Country

    United States of America

  • Sector

    Health Care

  • Industry group

    Pharmaceuticals, Biotechnology & Life Sciences

  • Industry

    Biotechnology

  • Sub-sector

    Health Care

  • Capitalization (millions of $)

    287340.5

  • Ticker

    ABBV.K

  • ISIN

    US00287Y1091

  • IPO date

    2013-01-02

  • Availability on Russian exchanges

    Yes

  • Reporting for

    2024-02-20

  • Date fact. publication of reports

    2023-12-31

Company Description

AbbVie Inc. (AbbVie) is a research-based biopharmaceutical company. The Company is engaged in research and development, manufacturing, commercialization and sale of medicines and therapies. AbbVie offers its products in various therapeutic categories, including Immunology products, which include Humira, Skyrizi and Rinvoq; Oncology products consists of Imbruvica and Venclexta; Aesthetics products include Botox Cosmetic, Juvederm Collection and other aesthetics; Neuroscience products, such as Botox Therapeutic, Vraylar, Duopa and Duodopa, and Ubrelvy; Eye care products consists of Lumigan, Alphagan and Restasis ; Women's health products incudes Lo Loestrin, Orilissa and other women's health; and Other key products, which includes Mavyret, Creon, Lupron, Linzess and Synthroid. The Company's products are sold worldwide directly to wholesalers, distributors, government agencies, health care facilities and independent retailers from AbbVie-owned distribution centers and public warehouses.